Why wait? The FDA stamps an ultra-fast OK on a HER2+ drug expected to create AstraZeneca's next blockbuster franchise
The FDA isn’t playing any waiting games when it comes to hustling up a quick OK for a breakthrough cancer drug.
In what has to be the fastest culmination of one of the smoothest multi-billion dollar alliances in biopharma history, the agency stamped their seal of marketing approval on trastuzumab deruxtecan, a remarkable new drug now ready to market at AstraZeneca and their partners at Daiichi Sankyo.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 70,200+ biopharma pros reading Endpoints daily — and it's free.